Table 4 Associations of the screening frequency of eGFR and potential covariates with significant eGFR reduction among patients with impaired kidney function (eGFR< 60 ml/min/1.73 m²)

eGFR screened yearly

Yes

77 (86.5)

12 (13.5)

No

361 (72.9)

134 (27.1)

2.38 (1.30–4.73, p = 0.008)

1.89 (0.61–7.21, p = 0.301)

Sex n (%)

Male

170 (71.1)

69 (28.9)

Female

268 (77.7)

77 (22.3)

0.71 (0.49–1.03, p = 0.073)

0.41 (0.20–0.84, p = 0.016)

Age, mean (SD)

81.5 (8.9)

82.5 (8.0)

1.01 (0.99–1.04, p = 0.201)

1.06 (1.01–1.12, p = 0.034)

LDL, n (%)

<  2.5 mmol/l

216 (73.2)

79 (26.8)

≥ 2.5 mmol/l

146 (79.3)

38 (20.7)

0.71 (0.45–1. 10, p = 0.130)

0.55 (0.24–1.18, p = 0.138)

HbA1c, n (%)

<  53 mmol/mol

264 (81.7)

59 (18.3)

≥ 53 mmol/mol

135 (64.6)

74 (35.4)

2.45 (1.65–3.67, p < 0.001)

0.82 (0.31–2.09, p = 0.679)

systolic BP, n (%)

<  135 mmHg

85 (75.2)

28 (24.8)

≥ 135 mmHg

97 (76.4)

30 (23.6)

0.94 (0.52–1.70, p = 0.835)

0.72 (0.36–1.41, p = 0.334)

ACEi/ARB in use

Yes

289 (73.2)

106 (26.8)

No

149 (78.8)

40 (21.2)

1.37 (0.91–2.08, p = 0.140)

5.16 (1.94–16.72, p = 0.002)

GLP-1 RAs in use

Yes

12 (85.7)

2 (14.3)

No

426 (74.7)

144 (25.3)

0.49 (0.08–1.84, p = 0.358)

0.95 (0.04–8.34, p = 0.965)

Any long-acting insulin in use

Yes

131 (61.5)

82 (38.5)

No

307 (82.7)

64 (17.3)

3.00 (2.05–4.43, p < 0.001)

2.01 (0.81–5.09, p = 0.133)

Statin in use

Yes

295 (75.4)

96 (24.6)

No

143 (74.1)

50 (25.9)

0.93 (0.63–1.39, p = 0.722)

0.59 (0.26–1.36, p = 0.210)